DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

American Well Corporation

New agreement integrates Dario's cardiometabolic suite into Amwell's market leading digital care delivery enablement platform covering over 90 million lives NEW YORK , March 22, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a strategic partnership with Amwell ® (NYSE: AMWL), a leader in digital healthcare enablement, to deliver its cardiometabolic solution to Amwell customers. Dario's solution will be available through Amwell beginning in the second half of 2023.

Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution

Dario's musculoskeletal solution uses data from a biofeedback sensor to drive healthier behaviors and reduce pain NEW YORK , March 14, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO)(the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today new research published in Pain Reports investigating personalized efficacy of digital therapeutics for pain management, linking the reduction of back pain for users in a digital posture training program with the personalization of user journeys adapting machine learning models.     The application of machine learning in digital health solutions is frequently cited as a means of delivering personalized programs, but our present understanding of the implications and outcomes is limited.

Dario Publishes New Research Demonstrating Digital Personalization of Pain Management with Adapted Machine Learning

DarioHealth Corp. (NASDAQ:DRIO ) Q4 2022 Results Conference Call March 9, 2023 8:30 PM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Charles Rhyee - TD Cowen Alexander Nowak - Craig-Hallum Capital Group Rahul Rakhit - LifeSci Capital Ben Haynor - Alliance Global Partners David Grossman - Stifel Operator Greetings, and welcome to the DarioHealth Fourth Quarter 2022 Results Call. At this time, all participants are in a listen only mode.

DarioHealth Corp. (DRIO) Q4 2022 Results Conference Call

Continued to improve the financial profile of the Company Full-year 2022 revenue of $27.7 million increased 34.8% over $20.5 million in 2021, as B2B revenue growth more than offset managed reduction of B2C activities Commercial revenue contributed 59% to 2022 full-year total revenue, compared to 4% for the full-year 2021 Gross margin was 40.1% of revenues for the fourth quarter of 2022, up from 9.1% of revenues for the fourth quarter of 2021 Pro-forma gross margin was 58% of revenues for the fourth quarter of 2022, up from 22% of revenues for the fourth quarter of 2021 58.4% reduction in operating loss in the fourth quarter 2022 as compared to the fourth quarter of 2021 Sequential 38.2% reduction in operating loss from the third quarter to fourth quarter of 2022 Ended 2022 with cash and cash equivalents of $49.3 million Company to host investor conference call and webcast at 8:30 a.m. ET today NEW YORK , March 9, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today reported financial results for the fourth quarter and full year 2022 and provided a corporate and commercial update.

DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results

Company to host conference call and webcast at 8:30 am ET NEW YORK , March 2, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 9, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, Rick Anderson, President, and Zvi Ben-David, Chief Financial Officer will host the call.

DarioHealth to Report Fourth Quarter 2022 Results on Thursday, March 9th

Dario demonstrates the impact of targeted coaching interventions in a digital-first chronic care solution Dario solution demonstrates significant impact on hypoglycemic events in senior populations NEW YORK , Feb. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2023, which was held February 22-25 in Berlin. One of the studies demonstrated improved clinical outcomes in users with Type 2 diabetes and provided further analysis to understand the mediating effects of live human coaching and digital interventions across the Dario user journey.

New Research from Dario Demonstrates Improved Clinical Outcomes in Two New Studies at the Advanced Technologies and Treatments for Diabetes 2023 Conference

NEW YORK , Feb. 24, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that management will participate in the Cowen 43nd Annual Healthcare Conference, which is being held March 6-8, 2023, at the Boston Marriott Copley Place in Boston, Massachusetts. Erez Raphael, Chief Executive Officer, and Rick Anderson, President, will participate in a fireside chat on Monday, March 6 th, from 10:30 – 11:00 AM ET.

DarioHealth to Participate in the Cowen 43rd Annual Healthcare Conference

Mr. Kaplan brings a wealth of experience in business strategy specifically in healthcare and digital health NEW YORK , Feb. 23, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the appointment of Jon Kaplan to serve as a board member effective immediately. Mr. Kaplan is a Managing Director and Senior Partner at Boston Consulting Group (BCG), serving as a core member of the strategy and health care practices and leading BCG's transformation initiative for the future evolution of healthcare in the United States and its impact globally.

Dario Appoints Industry Veteran Jon Kaplan to Board

DexCom

New integration will improve access to Dario's multi-chronic platform for more people living with diabetes NEW YORK , Feb. 8, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today an agreement with Dexcom (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring (CGM) technology, to integrate its market-leading CGMs, into Dario's multi-chronic condition platform.     Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health.

Dario Partners to Integrate Dexcom CGM Data

Preliminary Results demonstrate success in B2C to B2B transformation Total revenue for the year is expected to be $27.5 million compared to $20.5 million in 2021. B2B expected to represent approximately 60% of revenue in 2022 versus 4% in 2021 Continued improvement of Company's financial profile, reducing its operating loss by more than 50% compared to the fourth quarter of 2021.

DarioHealth Announces Preliminary Fourth Quarter and Full Year 2022 Operating Results

DarioHealth rallied off a low in December and since raced to new highs. Market generated data suggests the rally could extend over the coming weeks to months.

DarioHealth: January Rally Looks To Be Exhausting (Technical Analysis)

Matt Alberico joins Dario to help manage expanding growth opportunities after successfully driving customer growth at Amazon Care, Cigna and Aetna NEW YORK , Jan. 24, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the hire of seasoned industry sales leader Matt Alberico as Senior Vice President of Growth to help the Company capitalize on its rapidly growing opportunities across multiple market segments.   Mr. Alberico joins Dario after leading national channel sales and partnerships for Amazon Care.

Dario Adds New Senior Vice President of Growth to Expanding Sales Team

New York , Jan. 9, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the publication of new research in the peer-reviewed journal Applied Sciences demonstrating improved outcomes for users living with diabetes across different racial and ethnic groups. The research appears in the journal as part of the Special Issue: Digital Therapeutics Applications for Chronic Disease Management.

Dario Publishes New Research in Peer Reviewed Journal Demonstrating Improved Outcomes by Race and Ethnicity

Northeast supermarket chain will deploy Dario's cardiometabolic suite in 2023 NEW YORK , Jan. 3, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that a large Northeast U.S. supermarket chain (the "Employer") selected Dario to help improve the cardiometabolic health of its employees beginning in the first quarter of 2023, marking the Company reaching 100 enterprise contracts signed. This milestone achievement validates the Company's strategic position as a leading provider of integrated digital chronic condition management solutions in the employer and payer markets.

Dario Achieves Goal of 100 Business-to-Business Contracts in 2022

Dario Move to be deployed in Greece and Cyprus to help improve the musculoskeletal health of the general populations New York , Dec. 22, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a new partnership with ECES, a leading international wellness company, to deploy Dario Move throughout Greece and Cyprus as part of a planned government sponsored initiative. The program will launch in early 2023 with a mandate to screen a minimum of 50,000 citizens in support of improving musculoskeletal health of the Greek and Cyprus populations.

Leading International Wellness Company Selects Dario as Partner for Musculoskeletal Health Improvement Program

NEW YORK , Dec. 19, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced the publication of a new study in the peer-reviewed journal Frontiers in Physiology today demonstrating the effectiveness of the Company's musculoskeletal solution, which uses real-time biofeedback and behavior training to reduce back pain. Dario Move's posture training solution helps users develop better posture through the use of a wearable biofeedback device and real-time data feedback in the solution application.

New Research Published in Peer Reviewed Journal Demonstrating Dario's Musculoskeletal Solution Reduces Back Pain

The new accounts originated through an existing relationship with a benefits brokerage and provide further validation of Dario's partnership Strategy. NEW YORK , Dec. 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that two employers selected Dario as part of an offering from a leading benefits brokerage partner that Dario had previously announced (the "Partner").

Two New Employers Join Dario Through Benefits Brokerage Partner

We've revised our rating on DarioHealth to a buy, with consideration to tactical allocation for equity portfolios. DRIO's Q3 numbers came in strong with upsides versus consensus at the top and bottom lines.

DarioHealth: Market Sentiment Shift Post Q3 Numbers, Revise To Speculative Buy

NEW YORK , Nov. 16, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that management will participate at the following conferences: 13th Annual Craig-Hallum Alpha Select Conference  Format: Investor one-on-one meetingsDate: Thursday, November 17, 2022 Location: New York City, NY BTIG Digital Health Forum  Format: Investor one-on-one meetingsDate: November 21, 2022 Location: VirtualRick Anderson, President of Dario, will participate in the panel discussion "Moving Digital Devices and Therapeutics into the Mainstream" at 11:55 a.m. EST. For more information, please visit Craig-Hallum.com and BTIG.com.

Dario to Participate in Craig-Hallum and BTIG Digital Health

DarioHealth Corp. (NASDAQ:DRIO ) Q3 2022 Results Conference Call November 15, 2022 8:30 AM ET Company Participants Glenn Garmont - IR Erez Raphael - CEO Rick Anderson - President Conference Call Participants Charles Rhyee – Cowen Rahul Rakhit - LifeSci Capital David Grossman – Stifel Ben Haynor - Alliance Global Partners Chase Knickerbocker - Craig-Hallum Operator Good day, everyone, and welcome to the DarioHealth Third Quarter 2022 Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

DarioHealth Corp. (DRIO) Q3 2022 Earnings Call Transcript

Third quarter 2022 revenues of $6.6 million increased 17.3% from $5.6 million in the third quarter of 2021 driven by growth in Business-to-Business (B2B) revenues. Nine-month year to date revenue totaled $20.8 million, a 44% increase over the first nine months of 2021.

DarioHealth Reports Third Quarter 2022 Financial and Operating Results

Company to host conference call and webcast at 8:30 am ET the next day NEW YORK , Nov. 9, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022, after markets close. The company will host a conference call and webcast on Tuesday, November 15, 2022 at 8:30 am Eastern Time.

DarioHealth to Report Third Quarter 2022 Results on Monday, November 14th

New 'jumbo' employer account represents increasing penetration of the Dario platform NEW YORK , Oct. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the company's full suite of chronic condition management solutions were selected by two employers to help improve overall employee health beginning in the first quarter of 2023. The new accounts continue the rapid growth of Dario's business in the employer market and include a global Fortune 1000 company and a global sports organization.

Dario Announces Two Employer Contracts for Full Suite of Digital Health Solutions

Dario to support City employees with integrated solutions addressing diabetes, hypertension, weight management, musculoskeletal and behavioral health in company's first government contract win NEW YORK , Oct. 13, 2022 /PRNewswire/ -- DarioHealth Corp. ("Dario" or the "Company") (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that a mid-sized Midwestern city (the "City") selected Dario to provide its full suite of digital therapeutics solutions to several thousand city employees beginning in the first quarter of 2023. The contract is Dario's first with a government benefits entity, growing the Company's already robust employer footprint to include a new segment.

Dario's Full Suite of Digital Solutions Selected by Midwestern City to Improve Employee Health

New research sheds light on the importance of training to drive healthier posture  NEW YORK, Sept. 22, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research examining the link between the use of Dario's biofeedback device to help users improve their posture and reduced back pain at the International Association of the Study of Pain (IASP) 2022 World Congress on Pain, being held in person in Toronto, Ontario from September 19 th – 23rd and virtually.

News for DarioHealth Stock (DRIO)